Please Wait.....
Report
Europe Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other Consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Application (Oncological, Non-Oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Country, Competition, Forecast and Opportunities, 2020-2030F
Market Report I 2025-04-25 I 127 Pages I TechSci Research
Market Overview
The Europe Liquid Biopsy Market was valued at USD 1.16 billion in 2024 and is expected to grow to USD 1.86 billion by 2030, at a CAGR of 11.72%. This growth is driven by increasing demand for non-invasive diagnostic techniques and the rising incidence of cancer across the region. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, providing real-time insights into tumor genetics with minimal patient discomfort. As personalized medicine gains traction, liquid biopsy is being increasingly utilized to monitor disease progression and treatment response. Advancements in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome-based technologies are significantly improving diagnostic sensitivity and specificity. Government and private investments in cancer research, along with the integration of artificial intelligence in data interpretation, are further propelling the market. The growing application of liquid biopsy in early cancer detection, clinical trials, and companion diagnostics is helping to shape a more patient-centric, precision oncology landscape across Europe.
Key Market Drivers
Rising Incidence of Cancer
The increasing cancer burden in Europe is a key driver fueling the adoption of liquid biopsy technologies. With around 4.47 million new cancer cases reported in 2022 and an age-standardized rate of 280 per 100,000 individuals, the need for early, accurate, and less invasive diagnostic methods is more critical than ever. Liquid biopsy enables clinicians to detect cancer-related genetic mutations and alterations using bodily fluids such as blood, allowing for real-time disease monitoring, early diagnosis, and evaluation of treatment effectiveness. This non-invasive approach reduces the need for repeated tissue biopsies and aligns with the growing trend of personalized medicine. As cancer prevalence continues to rise, particularly in countries with robust healthcare systems, liquid biopsy is increasingly being integrated into clinical workflows to support improved patient outcomes and targeted therapy decisions.
Key Market Challenges
High Cost of Liquid Biopsy Tests
The elevated cost of liquid biopsy tests remains a substantial challenge for the Europe Liquid Biopsy Market. These tests often rely on high-end technologies like next-generation sequencing (NGS), digital PCR, and complex multi-omics platforms that demand advanced lab infrastructure and skilled personnel. Comprehensive tests analyzing multiple biomarkers can be particularly expensive, limiting their affordability for many patients and straining healthcare budgets. Reimbursement policies vary across Europe, with limited or inconsistent coverage posing a barrier to broader clinical adoption. This disparity affects patient access, especially for those in early-stage diagnosis or asymptomatic phases. Consequently, even when liquid biopsy offers clear clinical benefits, its use may be restricted by economic constraints unless reimbursement frameworks evolve to support its widespread integration into standard care.
Key Market Trends
Integration of Liquid Biopsy with Companion Diagnostics
The combination of liquid biopsy and companion diagnostics is becoming a transformative trend in the Europe Liquid Biopsy Market. Companion diagnostics enable the identification of patients most likely to benefit from specific therapies by detecting relevant genetic biomarkers. When coupled with liquid biopsy, these diagnostics become more accessible, non-invasive, and practical for continuous monitoring. This approach supports the rising demand for precision oncology, allowing for tailored therapies and real-time adjustments based on the patient's evolving tumor profile. Pharmaceutical companies are increasingly collaborating with diagnostics developers to create integrated drug-diagnostic platforms, which are being utilized in both clinical trials and routine care. Regulatory support and the ability to track resistance mutations and tumor evolution further enhance the utility of these solutions. This trend is central to advancing precision medicine in Europe, improving treatment efficacy, and minimizing costs from ineffective therapies.
Key Market Players
- QIAGEN N.V.
- Epigenomics AG
- Inivata Ltd.
- Sysmex Inostics GmbH
- Stilla Technologies
- Novigenix SA
- Eurofins Genomics Europe
- Chronix Biomedical GmbH
- Genseq Ltd.
- Blueberry Therapeutics Ltd.
Report Scope:
In this report, the Europe Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Europe Liquid Biopsy Market, By Offering:
o Testing Services
o Kits
o Platform
o Other Consumables
- Europe Liquid Biopsy Market, By Technology:
o Polymerase Chain Reaction (PCR)
o Next Generation Sequencing (NGS)
o Others
- Europe Liquid Biopsy Market, By Application:
o Oncological
o Non-Oncological
- Europe Liquid Biopsy Market, By End User:
o Clinical Laboratories
o Academic & Research Institutes
o Pharmaceutical & Biotechnology Companies
- Europe Liquid Biopsy Market, By Country:
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Poland
o Bulgaria
o Finland
o Portugal
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Europe Liquid Biopsy Market.
Available Customizations:
Europe Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Europe Liquid Biopsy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
5.2.3. By Application (Oncological, Non-Oncological)
5.2.4. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
5.2.5. By Country
5.2.6. By Company (2024)
5.3. Market Map
6. Germany Liquid Biopsy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Offering
6.2.2. By Technology
6.2.3. By Application
6.2.4. By End User
7. France Liquid Biopsy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering
7.2.2. By Technology
7.2.3. By Application
7.2.4. By End User
8. United Kingdom Liquid Biopsy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering
8.2.2. By Technology
8.2.3. By Application
8.2.4. By End User
9. Italy Liquid Biopsy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End User
10. Spain Liquid Biopsy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering
10.2.2. By Technology
10.2.3. By Application
10.2.4. By End User
11. Russia Liquid Biopsy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering
11.2.2. By Technology
11.2.3. By Application
11.2.4. By End User
12. Poland Liquid Biopsy Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Offering
12.2.2. By Technology
12.2.3. By Application
12.2.4. By End User
13. Bulgaria Liquid Biopsy Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Offering
13.2.2. By Technology
13.2.3. By Application
13.2.4. By End User
14. Finland Liquid Biopsy Market Outlook
14.1. Market Size & Forecast
14.1.1. By Value
14.2. Market Share & Forecast
14.2.1. By Offering
14.2.2. By Technology
14.2.3. By Application
14.2.4. By End User
15. Portugal Liquid Biopsy Market Outlook
15.1. Market Size & Forecast
15.1.1. By Value
15.2. Market Share & Forecast
15.2.1. By Offering
15.2.2. By Technology
15.2.3. By Application
15.2.4. By End User
16. Market Dynamics
16.1. Drivers
16.2. Challenges
17. Market Trends & Developments
17.1. Merger & Acquisition (If Any)
17.2. Product Launches (If Any)
17.3. Recent Developments
18. Europe Liquid Biopsy Market: SWOT Analysis
19. Porters Five Forces Analysis
19.1. Competition in the Industry
19.2. Potential of New Entrants
19.3. Power of Suppliers
19.4. Power of Customers
19.5. Threat of Substitute Products
20. Competitive Landscape
20.1. QIAGEN N.V.
20.1.1. Business Overview
20.1.2. Company Snapshot
20.1.3. Products & Services
20.1.4. Financials (As Reported)
20.1.5. Recent Developments
20.1.6. Key Personnel Details
20.1.7. SWOT Analysis
20.2. Epigenomics AG
20.3. Inivata Ltd.
20.4. Sysmex Inostics GmbH
20.5. Stilla Technologies
20.6. Novigenix SA
20.7. Eurofins Genomics Europe
20.8. Chronix Biomedical GmbH
20.9. Genseq Ltd.
20.10. Blueberry Therapeutics Ltd.
21. Strategic Recommendations
22. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security